Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Pimozide Tablet Market Expected To Reach $2.9 Billion By 2030 At 9.5% CAGR
The market for pimozide tablets has experienced notable expansion over the past few years. Projections indicate a rise from $1.84 billion in 2025 to $2.02 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.9%. This historical growth has been driven by restricted therapeutic alternatives for Tourette’s syndrome, a higher incidence of chronic schizophrenia, enhanced hospital and clinic facilities, greater recognition of antipsychotic treatments, and continued dependence on conventional brick-and-mortar pharmacies.
The pimozide tablet market is anticipated to experience robust expansion over the coming years, with its value projected to reach $2.91 billion by 2030, reflecting a compound annual growth rate (CAGR) of 9.5%. This growth during the forecast period is driven by the creation of low-dose and unit-dose pimozide tablets, the growing presence of online pharmacy services, the increasing trend of home healthcare adoption, heightened government initiatives targeting mental health, and the integration of digital tools for medication adherence monitoring. Key trends influencing this period encompass a rising awareness of Tourette’s syndrome and chronic schizophrenia, a growing preference for oral antipsychotic medications, a surge in home-based mental health care and therapy, the broadening of online pharmaceutical distribution channels, and the advancement of personalized dosing and packaging options.
Download A Free Sample Report For Comprehensive Market Insights:
Pimozide Tablet Market Expansion Supported By Key Demand Factors
The growing incidence of psychiatric disorders is anticipated to boost the pimozide tablet market in the upcoming period. These disorders are mental health conditions marked by major disruptions in thinking, emotions, or behavior, resulting in distress or compromised functionality. This rise in psychiatric conditions is largely due to heightened stress, shifting social standards, improved diagnosis and awareness, and genetic vulnerabilities. Pimozide tablets are employed to treat symptoms like delusions and tics by blocking dopamine receptors, thus lowering irregular brain activity. For example, in August 2025, the Substance Abuse and Mental Health Services Administration (SAMHSA), a U.S. federal agency, reported that 23.4% of adults aged 18 and older (roughly 61.5 million individuals) had any mental illness (AMI), with about 5.6% experiencing a serious mental illness (SMI). In comparison, data from 2023 showed 22.8% (58.7 million people) and 5.7% (14.6 million people) of adults reported AMI and SMI, respectively. Consequently, the increasing prevalence of psychiatric disorders is fueling the pimozide tablet market.
Higher healthcare spending is set to drive the pimozide tablet market forward in the future. This spending is climbing due to the growing costs of advanced medical technologies, aging demographics, and the rising burden of chronic illnesses. As healthcare expenditure increases, it improves access to mental health services and expands insurance coverage for psychiatric drugs, thereby boosting demand for Pimozide tablets. Take, for instance, May 2024 data from the Office for National Statistics, a UK government agency, which showed that healthcare spending in the UK went from £277 ($319.91) billion in 2022 to £292 ($337.23) billion in 2023, marking a nominal increase from the prior year. Therefore, the rise in healthcare expenditure is propelling the pimozide tablet market forward.
Growing investments in pharmaceutical manufacturing are expected to accelerate the pimozide tablet market in the coming period. This sector involves creating medicines through combining, processing, and packaging chemical or biological substances under rigorous quality controls to guarantee safety, efficacy, and patient suitability. The expansion in pharmaceutical manufacturing is driven by a rising need for affordable generic medications, prompting companies to boost output to address patient healthcare demands. Pimozide tablets support this manufacturing landscape by offering a marketable central nervous system drug that stimulates production, formulation, and distribution activities. For example, in June 2025, Les Entreprises du Médicament (Leem), a French professional body for pharmaceutical firms, noted that manufacturing-related investments in France grew by 38% in 2024 compared to 2023. Thus, increased investment in pharmaceutical manufacturing is fueling the pimozide tablet market growth.
Pimozide Tablet Market Segment Landscape And Growth Potential
The pimozide tablet market covered in this report is segmented –
1) By Type: 1 Milligram, 2 Milligram, 4 Milligram
2) By Distribution Channel: Online, Offline
3) By Application: Tourette’s Syndrome, Chronic Schizophrenia
4) By End User: Hospitals, Clinics, Home Use
Pimozide Tablet Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the pimozide tablet market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Novartis AG, Bristol-Myers Squibb, GlaxoSmithKline plc, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Hetero Drugs, Sun Pharmaceutical Industries Ltd., Jazz Pharmaceuticals, Aurobindo Pharma, Cipla Limited, Apotex Inc., H. Lundbeck A/S, Dr. Reddy’s Laboratories, Hikma Pharmaceuticals, Amneal Pharmaceuticals, Endo International, Lupin Limited, Zydus Cadila, Alkem Laboratories, Torrent Pharmaceuticals, Glenmark Pharmaceuticals, Mallinckrodt Pharmaceuticals, Jubilant Life Sciences, Alembic Pharmaceuticals, Wockhardt, AA Pharma, Taj Pharmaceuticals
Access The Complete Pimozide Tablet Market Report:
Pimozide Tablet Market Geographic Distribution And Regional Opportunities
North America was the largest region in the pimozide tablet market in 2025. The regions covered in the pimozide tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model